Aquestive Therapeutics, Inc.【AQST】 業績推移・財務諸表

(単位:千ドル) 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 1Q22 2Q22 3Q22 1Q23 2Q23 3Q23 1Q24 2Q24 3Q24 1Q25
売上高 13,928 13,267 16,824 12,643 11,129 12,418 16,419 8,765 21,675 8,260 7,149 11,122 15,345 13,287 12,270 13,265 11,463 11,134 13,241 13,002 12,053 20,099 13,542 8,720
売上成長率(%) - - - -
売上原価 - - - - - - - - 3,539 2,978 2,788 2,757 4,466 4,400 4,214 5,242 4,625 4,737 6,617 4,798 4,389 4,526 4,437 3,652
研究開発費 7,994 4,534 - 4,303 8,151 5,063 - 4,354 3,847 7,260 - 3,659 4,262 4,726 4,773 5,198 3,232 3,547 3,473 3,196 5,932 4,162 5,269 5,361
販売管理費 33,647 12,345 - 17,908 16,246 13,714 - 14,613 13,894 11,803 - 13,231 13,134 12,129 13,021 15,587 12,459 7,455 7,360 7,385 10,689 11,356 12,126 19,072
営業費用 46,614 22,471 29,173 25,717 29,817 23,420 26,323 22,626 21,280 22,041 22,795 19,647 21,862 21,255 22,008 26,027 20,316 15,739 17,450 15,379 21,010 20,044 21,832 28,085
営業利益 -32,686 -9,204 - -13,074 -18,688 -11,002 - -13,861 395 -13,781 - -8,525 -6,517 -7,968 -9,738 -12,762 -8,853 -4,605 -4,209 -2,377 -8,957 55 -8,290 -19,365
営業利益率 (%) - - -
経常(税引前)利益 -36,493 -15,038 - -14,726 -20,472 -18,412 - -16,530 -2,334 -16,551 - -14,672 -12,367 -14,555 -13,220 -16,302 -12,536 8,068 -5,508 -2,175 -12,828 -2,745 -11,509 -22,930
経常(税引前)利益率(%) -262.01 -113.35 - -116.48 -183.95 -148.27 - -188.59 -10.77 -200.38 - -131.92 -80.59 -109.54 -107.74 -122.89 -109.36 72.46 -41.6 -16.73 -106.43 -13.66 -84.99 -262.96
法人税等合計 0 0 - 0 0 0 - 0 0 0 - 0 - - - - - 0 284 -140 - - - -
実効税率(%) - - - - - - - - - - - -
純利益 -36,493 -15,038 -13,944 -14,726 -20,472 -18,412 -12,636 -16,530 -2,334 -16,551 -20,368 -14,672 -12,367 -14,555 -13,220 -16,302 -12,536 8,068 -5,792 -2,035 -12,828 -2,745 -11,509 -22,930
純利益率(%)
一株あたり利益 - - - - - - - - - - - -0.41 -0.33 -0.37 -0.32 -0.36 -0.23 0.15 -0.1 -0.03 -0.17 -0.03 -0.13 -0.24
希薄化後一株あたり利益 - - - - - - - - - - - -0.41 -0.33 -0.37 -0.32 -0.36 -0.23 0.11 -0.1 -0.03 -0.17 -0.03 -0.13 -0.24
EBITDA - - - - - - - - - - - - - - - - - - - - - -
EBITDAマージン(%) - - - - - - - - - - - - - - - - - - - - - -